R&D

Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated

Retrieved on: 
Thursday, April 25, 2024
Compass, FDA, FTD, Paclitaxel, Food, BTC, Survival, R&D, MD, Doctor of Philosophy, Fast track (FDA), Observation, Therapy, Patient, Pharmaceutical industry

CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study

Key Points: 
  • CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study
    Top-line data readout for COMPANION-002, the Company’s randomized Phase 2/3 BTC U.S. study, is expected by the end of 2024
    BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation (FTD) to CTX-009, the Company’s bispecific DLL4/VEGF-A antibody, in combination with paclitaxel for the treatment of patients with metastatic or locally advanced BTC that have been previously treated.
  • “We are delighted that CTX-009 has received FDA Fast Track Designation highlighting the large unmet need in patients with advanced BTC where current therapies have low, single digit response rates, and limited effect on patient survival,” said Thomas Schuetz, MD, PhD, Co-founder, President of R&D, and Vice Chairman of the Compass board.
  • “Our current study is evaluating the combination of CTX-009 with paclitaxel following the observation of nine partial responses in 24 patients treated in our Phase 2 study, leading to an overall response rate of 37.5% (n= 9/24), a median progression free survival of 9.4 months and a median overall survival of 12.5 months.
  • Compass remains on track to complete enrollment by mid-year and reporting top-line data by year end.”

BuzzBallz Releases New Passionfruit Martini Flavor in US After UK Success

Retrieved on: 
Monday, April 15, 2024
BuzzBallz, Glass, Social media, Vanilla, Travel, Marketing, R&D, Cocktail, Chiller, Max Martini, Liquor

Carrollton, TX, April 15, 2024 (GLOBE NEWSWIRE) -- After a successful launch in their United Kingdom markets, BuzzBallz is bringing its new Passionfruit Martini flavor to United States stores.

Key Points: 
  • Carrollton, TX, April 15, 2024 (GLOBE NEWSWIRE) -- After a successful launch in their United Kingdom markets, BuzzBallz is bringing its new Passionfruit Martini flavor to United States stores.
  • The ready-to-drink cocktail will be available in both their spirit-based BuzzBallz Cocktails and wine-based BuzzBallz Chillers lines.
  • The BuzzBallz Passionfruit Martini provides a perfect solution for those interested in trying the cocktail even with no mixology experience or equipment.
  • The BuzzBallz Passionfruit Martini will begin shipping to US markets in April 2024.

Xaira Therapeutics Launches to Deliver Transformative Medicines by Advancing and Harnessing AI for Drug Discovery and Development

Retrieved on: 
Wednesday, April 24, 2024
Data Management, Health, Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, Ron Conway, Element, Biochemistry, ARCH Venture Partners, AI, Sequoia Capital, Systems biology, Intelligence, SVP, Medicine, Howard Hughes Medical Institute, Drug discovery, Onyx Pharmaceuticals, Food, EVP, R&D, Machine learning, Nobel Prize, NEA, Entrepreneurship, CIO, Boston Consulting Group, Therapy, Lux Capital, Foresite Capital, Executive, Lightspeed Venture Partners, Johnson & Johnson, Proteomics, Meta, Rockefeller University, Chemistry, Biology, Former, Drug development, Menlo Ventures, Interline, Stanford University, University, Food and Drug Administration, Disease, Patient, Senior advisor, Pharmaceutical industry

Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.

Key Points: 
  • Xaira Therapeutics launched today on a mission to help re-engineer the way we discover and develop medicines through the end-to-end application of emerging AI technologies.
  • Xaira brings together three core elements: advanced machine learning research, expansive data generation to power new models, and robust therapeutic product development.
  • With leading talent and capabilities in each area, Xaira is building a platform for drug discovery and development that will advance multiple drug programs and unlock biological understanding to inform future discovery.
  • Xaira is building significant AI research capabilities spanning fundamental computational methods development and their application to biological discovery, the design of drug-like matter, and clinical development.

ElevateBio Announces Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting

Retrieved on: 
Monday, April 22, 2024
Biotechnology, Health Technology, Genetics, Health, Small RNA, R&D, Annual general meeting, Gene, Cell, Society, AAV

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, in Baltimore, MD.

Key Points: 
  • ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering the creation of life-transforming genetic medicines, today announced four poster presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, in Baltimore, MD.
  • The poster presentations will detail ElevateBio’s expertise in optimizing the development and manufacturing of genetic medicines, including scalable screening and manufacturing processes for adeno-associated virus (AAV) vectors for gene therapies, a proprietary CAR/TCR platform that accelerates the nomination of therapeutic receptors for faster development of engineering cell therapies, and an efficient, scalable process to produce high purity circularRNA (circRNA) for potential therapeutic applications both ex vivo and in vivo.
  • “These data underscore our commitment to developing scalable solutions and capabilities to accelerate cell and gene therapy development,” said Mitchell Finer, Ph.D., President, R&D, ElevateBio.
  • “As a technology-forward company, we’re thrilled to showcase these latest advancements that are fueling the programs of our partners and moving the industry forward.”

M31 has successfully launched MIPI C/D PHY Combo IP on the advanced TSMC 5nm process

Retrieved on: 
Thursday, April 25, 2024
Internet of things, TSMC, IP, AI, PCI Express, Silicon, IPS, OIP, R&D, PHY, Standard cell, ADAS, Artificial intelligence, ALP, MIPI, GPIO, Intellectual property, Multimedia, M31, Partner, Socs

HSINCHU, April 25, 2024 /PRNewswire/ -- M31 Technology Corporation (M31), a leading global provider of silicon intellectual property (IP), announced that the M31 MIPI C/D-PHY Combo IP has obtained silicon validation on the advanced TSMC 5nm process and the company has already started 3nm IP development.

Key Points: 
  • HSINCHU, April 25, 2024 /PRNewswire/ -- M31 Technology Corporation (M31), a leading global provider of silicon intellectual property (IP), announced that the M31 MIPI C/D-PHY Combo IP has obtained silicon validation on the advanced TSMC 5nm process and the company has already started 3nm IP development.
  • M31 has been honored with the TSMC Open Innovation Platform® (OIP) Partner of the Year Award for Special Process IP for six consecutive years.
  • M31 also introduced the 5nm MIPI C/D PHY Combo IP that complies with the latest D-PHY v2.5 and C-PHY v2.0 specifications.
  • Looking ahead, M31 will closely follow TSMC's advanced process technology, continue to invest in R&D resources, develop products using advanced process technology, and expand IP solutions in emerging application areas such as AI, IoT, and 5G communication, to help customers accelerate product launches and enhance market competitiveness."

CleanTech Strategies Selected by U.S. Department of Energy to Advance Innovations in Flow Batteries, with Close Industry Collaboration

Retrieved on: 
Tuesday, April 23, 2024
Public sector, DOE, EEI, Storage, PNNL, BCI, Pacific Northwest National Laboratory, R&D, Partnership, Office of Electricity, Research, Battery Council International, Inflation, EPRI, Edison Electric Institute, Private sector, CTS, OE, Electric Power Research Institute, Clean technology, Knowledge, Renewable energy

SEATTLE, April 23, 2024 /PRNewswire/ -- Clean technology expert firm CleanTech Strategies (CTS) has been selected by the U.S. Department of Energy (DOE)'s Office of Electricity (OE) as one of three selectees to receive a $5 million award each to advance energy storage innovations to help deliver clean, affordable electricity to Americans. The DOE OE awards are through the Storage Innovations 2030: Technology Liftoff funding opportunity announcement.

Key Points: 
  • SEATTLE, April 23, 2024 /PRNewswire/ -- Clean technology expert firm CleanTech Strategies (CTS) has been selected by the U.S. Department of Energy (DOE)'s Office of Electricity (OE) as one of three selectees to receive a $5 million award each to advance energy storage innovations to help deliver clean, affordable electricity to Americans.
  • CTS appreciates DOE OE's further support of flow battery innovations, building on its sustained efforts for two decades.
  • CTS very much appreciates DOE OE's further support of flow battery innovations under the Storage Innovations 2030 program, which builds on its sustained efforts for two decades."
  • FBIG was established in 2023 as part of BCI in collaboration with CTS, and has grown into an industry-leading platform for industry collaboration and advancement.

Winter tests prove BWI Group's top technology

Retrieved on: 
Monday, March 11, 2024
Culture, Brake, MagneRide, Noise, BeijingWest Industries, Electronic parking brake, The central science, EMB, Safety, R&D, Snow, Instrumentation

BEIJING, March 11, 2024 /PRNewswire/ -- BWI Group conducted dynamic extreme-cold tests for the quality and performance of the product lineup installed on all-new mainstream car models in Europe, North America and Asia, while its revolutionary Electro Mechanic Braking technology dynamic test wrapped up on Mar 8.

Key Points: 
  • As the world's leading tier one supplier, BWI Group insists on carrying out winter tests in three continents, which not only proves the performance and working status of the Group's intelligent chassis products in real snow and cold conditions, but also reflects the more stringent global R&D standards of BWI Group.
  • George Chang, member of Board of Directors and Global CEO of BWI Group said, "Our products are sold globally alongside vehicle products from over 50 customers worldwide.
  • Consequently, BWI Group must adhere to increasingly rigorous international technical standards throughout the entire R&D to production process.
  • For instance, we firmly maintain conducting extreme cold tests annually in China, the United States, and Europe to fulfill the demands of international standards."

Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial

Retrieved on: 
Wednesday, February 28, 2024
FDA, Therapy, R&D, MD, IND, Doctor of Philosophy, CD137, PD-1, PD-L1, Pharmaceutical industry

CTX-8371 is a fully-human, tetravalent bispecific antibody, discovered and developed by Compass Therapeutics as a next generation checkpoint blocker.

Key Points: 
  • CTX-8371 is a fully-human, tetravalent bispecific antibody, discovered and developed by Compass Therapeutics as a next generation checkpoint blocker.
  • The data highlighted the unique mechanism-of-action of CTX-8371, inducing dual blockade of PD-1 and PDL-1 and cleavage of cell surface PD-1.
  • In addition, CTX-8371 demonstrates enhanced anti-tumor activity relative to approved anti-PD-1 blockers and anti-PD-L1 blockers in a series of in vitro and in vivo experimental settings.
  • “These compelling data are a testament to the functionality of our novel checkpoint inhibitor and we are excited to continue evaluating its potential in clinical studies.

Sinotruk leaping forward to become world-class technology enterprise

Retrieved on: 
Saturday, March 2, 2024
Life, Science, Yellow, R&D, Research, Conference

Over the past five years, Sinotruk has invested nearly RMB 15 billion in R&D, which is the sum of the previous 15 years.

Key Points: 
  • Over the past five years, Sinotruk has invested nearly RMB 15 billion in R&D, which is the sum of the previous 15 years.
  • Sinotruk technological strength has reached the forefront of the national industry.
  • Sinotruk has reshaped the "Yellow River" heavy-duty trucks standard with technology, ranking first in China, and its high-tech indicators are leading the industry.
  • Let's set off again for a better future for the century heavy truck industry and the world's best heavy truck industry!

Global 3D Printed Wearables Market Analysis Report 2023-2030: Innovative Hybrid 3D Printing Technology Promises Precision and Cost Efficiency - ResearchAndMarkets.com

Retrieved on: 
Friday, January 12, 2024
Technology, Consumer Electronics, Biotechnology, R&D, 3D, COVID-19, Wyss Institute, Harvard University, USD, Hospital, Growth, Video game

The "Global 3D Printed Wearables Market Size, Share & Trends Analysis Report by Product Type (Prosthetics, Orthopedic Implants), End-use (Hospital, Pharma & Biotech Companies), Region, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global 3D Printed Wearables Market Size, Share & Trends Analysis Report by Product Type (Prosthetics, Orthopedic Implants), End-use (Hospital, Pharma & Biotech Companies), Region, and Segment Forecasts, 2023-2030" report has been added to ResearchAndMarkets.com's offering.
  • The global 3D printed wearables market size is expected to reach USD 6.67 billion by 2030, registering a CAGR of 8.0%
    3D printed wearable technology has witnessed high adoption in the healthcare industry.
  • Due to numerous technological innovations in the sector, the market is expected to witness significant growth over the forecast period.
  • In the first quarter of 2020, the COVID-19 outbreak disrupted the global supply chain of raw materials and manufacturing parts of 3D printing products.